Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Discover 13 Promising Stocks Set to Skyrocket -
Unlock Our Top Picks Today
Unlock Our Top Picks Today
Venus Remedies is currently trading at Rs. 276.30, up by 8.50 points or 3.17% from its previous closing of Rs. 267.80 on the BSE.
The scrip opened at Rs. 269.00 and has touched a high and low of Rs. 279.25 and Rs. 268.10 respectively. So far 22,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 308.45 on 11-Sep-2012 and a 52 week low of Rs. 141.05 on 22-Dec-2011.
Last one week high and low of the scrip stood at Rs. 300.55 and Rs. 262.05 respectively. The current market cap of the company is Rs. 269.00 crore.
The promoters holding in the company stood at 34.71% while Institutions and Non-Institutions held 14.54% and 50.76% respectively.
Venus Remedies has won Manufacturing Award for its world class manufacturing and operational excellence at the ‘Industry 2.0 Manufacturing Innovation Conclave 2012’. Being in the highly regulated Pharmaceutical industry, the company’s three manufacturing facilities has 15 national and international GMP certifications to its credit, which includes EUROPEAN-GMP, WHO-GMR GCC-GMP, Latin American GMP (INVIMA) and many more.
Apart from this, the company has won ‘Silver Certificate of Merit’ in the Economic Times’ India Manufacturing Excellence Awards (IMEA), 2011 in recognition and acknowledgment of Venus’s high standards in terms of its manufacturing practices, quality, regulatory approvals, significant investment on its state-of-the-art R&D centre, well equipped facilities and fine infrastructure.
Venus Remedies has a presence in both the branded and generic products segments of the pharmaceutical industry, especially in the critical-care segment. The company with its manufacturing units in Panchkula (Haryana) and Baddi (Himachal Pradesh) manufactures large- and small-volume parenterals, mainly in the antibiotics and oncology segments. The company accesses the European market through its wholly owned subsidiary, VP, based in Germany.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1504.75 |
| Dr. Reddys Lab | 6045.00 |
| Cipla | 1540.70 |
| Zydus Lifesciences | 1096.45 |
| Lupin | 1607.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
